About Kures
Kures is a company based in New York (United States) founded in 2015 by Andrew Kruegel was acquired by ATAI in July 2020. Kures has raised $4.24 million across 1 funding round from investors including ATAI. Kures operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
- Headquarter New York, United States
- Founders Andrew Kruegel
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Kures
Kures has successfully raised a total of $4.24M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.24 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kures
Kures has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include ATAI.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A biopharmaceutical company accelerating innovative mental health treatments.
|
Locked | Locked | Locked |
Investor details for Kures
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kures
Investment portfolio details for Kures
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kures
Detailed financials for Kures
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kures Comparisons
Peer comparison for Kures
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kures
Kures operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| Locked | Locked | Locked |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| Locked | Locked | Locked |
Therapies for central nervous system diseases and pain are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for mental health conditions are developed using serotonergic psychedelics.
|
|
| Locked | Locked | Locked |
Therapeutics for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
Detailed competitors of Kures
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kures
Complete news archive for Kures
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kures
Kures was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Kures is headquartered in New York, United States. It is registered at New York, New York, United States.
Kures is a funded company, having raised a total of $4.24M across 1 funding round to date.
Kures was established in 2015 and is based in New York, United States. Therapeutics utilizing opioids are developed by the company to address mood and depression disorders within the biotechnology sector. Operations focus on research and development of these treatments, with Andrew Kruegel serving as co-founder. Activities are centered in the United States, targeting unmet needs in mental health therapeutics.
Kures's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
Kures has 1 investor. Key investors include ATAI.